Search

Your search keyword '"Tang, W.H. Wilson"' showing total 710 results
Start Over Author "Tang, W.H. Wilson" Search Limiters Full Text
710 results on '"Tang, W.H. Wilson"'

6. Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality

Author

Alves, Renato, Amouyal, Chloe, Andersson Galijatovic, Ehm Astrid, Andreelli, Fabrizio, Barthelemy, Olivier, Bastard, Jean-Philippe, Batisse, Jean-Paul, Berland, Magalie, Bittar, Randa, Blüher, Matthias, Bork, Peer, Bourron, Olivier, Camus, Mickael, Cassuto, Dominique, Ciangura, Cecile, Coelho, Luis Pedro, Collet, Jean-Philippe, Dumas, Marc-Emmanuel, Ehrlich, S. Dusko, Engelbrechtsen, Line, Fezeu, Leopold, Forslund, Sofia, Fromentin, Sebastien, Galan, Pilar, Giral, Philippe, Gøtze, Jens Peter, Hansen, Torben, Hansen, Tue H., Hartemann, Agnes, Hartmann, Bolette, Hercberg, Serge, Holmes, Bridget, Holst, Jens Juul, Hornbak, Malene, Hoyles, Lesley, Hulot, Jean-Sebastien, Jaqueminet, Sophie, Kerneis, Mathieu, Khemis, Jean, Kozlowski, Ruby, Pedersen, Helle Krogh, Kuhn, Michael, Mannerås-Holm, Louise, Marko, Lajos, Martinez-Gili Robin Massey, Laura, Maziers, Nicolas, Medina-Stamminger, Jonathan, Moitinho-Silva, Lucas, Montalescot, Gilles, Moutel, Sandrine, Neves, Ana Luisa, Olanipekun, Michael, Oppert, Jean-Michel, Poitou, Christine, Pousset, Francoise, Pouzoulet, Laurence, Rouault, Christine, Silvain, Johanne, Vestergaard, Henrik, Molinaro, Antonio, Nemet, Ina, Bel Lassen, Pierre, Chakaroun, Rima, Nielsen, Trine, Aron-Wisnewsky, Judith, Bergh, Per-Olof, Li, Lin, Henricsson, Marcus, Køber, Lars, Isnard, Richard, Helft, Gerard, Stumvoll, Michael, Pedersen, Oluf, Smith, J. Gustav, Tang, W.H. Wilson, Clément, Karine, Hazen, Stanley L., and Bäckhed, Fredrik

Published
2023
Full Text
View/download PDF

10. Classification and Predictors of Right Ventricular Functional Recovery in Pulmonary Arterial Hypertension

Author

Rischard, Franz P., Bernardo, Roberto J., Vanderpool, Rebecca R., Kwon, Deborah H., Acharya, Tushar, Park, Margaret M., Katrynuik, Austin, Insel, Michael, Kubba, Saad, Badagliacca, Roberto, Larive, A. Brett, Naeije, Robert, Garcia, Joe G.N., Beck, Gerald J., Erzurum, Serpil C., Frantz, Robert P., Hassoun, Paul M., Hemnes, Anna R., Hill, Nicholas S., Horn, Evelyn M., Leopold, Jane A., Rosenzweig, Erika B., Tang, W.H. Wilson, and Wilcox, Jennifer D.

Published
2023
Full Text
View/download PDF

12. Pulmonary hypertension across the spectrum of left heart and lung disease

Author

Borlaug, Barry A., primary, Larive, Brett, additional, Frantz, Robert P., additional, Hassoun, Paul, additional, Hemnes, Anna, additional, Horn, Evelyn, additional, Leopold, Jane, additional, Rischard, Franz, additional, Berman‐Rosenzweig, Erika, additional, Beck, Gerald, additional, Erzurum, Serpil, additional, Farha, Samar, additional, Finet, J. Emanuel, additional, Highland, Kristin B., additional, Jacob, Miriam, additional, Jellis, Christine, additional, Mehra, Reena, additional, Renapurkar, Rahul, additional, Singh, Harsimran, additional, Tang, W.H. Wilson, additional, Vanderpool, Rebecca, additional, Wilcox, Jennifer, additional, Yu, Shilin, additional, and Hill, Nicholas, additional

Published
2024
Full Text
View/download PDF

14. Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease

Author

Hemnes, Anna R., Leopold, Jane A., Radeva, Milena K., Beck, Gerald J., Abidov, Aiden, Aldred, Micheala A., Barnard, John, Rosenzweig, Erika B., Borlaug, Barry A., Chung, Wendy K., Comhair, Suzy A.A., Desai, Ankit A., Dubrock, Hilary M., Erzurum, Serpil C., Finet, J. Emanuel, Frantz, Robert P., Garcia, Joe G.N., Geraci, Mark W., Gray, Michael P., Grunig, Gabriele, Hassoun, Paul M., Highland, Kristin B., Hill, Nicholas S., Hu, Bo, Kwon, Deborah H., Jacob, Miriam S., Jellis, Christine L., Larive, A. Brett, Lempel, Jason K., Maron, Bradley A., Mathai, Stephen C., McCarthy, Kevin, Mehra, Reena, Nawabit, Rawan, Newman, John H., Olman, Mitchell A., Park, Margaret M., Ramos, Jose A., Renapurkar, Rahul D., Rischard, Franz P., Sherer, Susan G., Tang, W.H. Wilson, Thomas, James D., Vanderpool, Rebecca R., Waxman, Aaron B., Wilcox, Jennifer D., Yuan, Jason X.-J., and Horn, Evelyn M.

Published
2022
Full Text
View/download PDF

22. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial

Author

Martens, Pieter, Dauw, Jeroen, Verbrugge, Frederik H., Nijst, Petra, Meekers, Evelyne, Augusto, Silvio Nunes, Jr, Ter Maaten, Jozine M., Damman, Kevin, Mebazaa, Alexandre, Filippatos, Gerasimos, Ruschitzka, Frank, Tang, W.H. Wilson, Dupont, Matthias, and Mullens, Wilfried

Published
2023
Full Text
View/download PDF

23. Consensus conference on heart-kidney transplantation

Author

Kobashigawa, Jon, Dadhania, Darshana M., Farr, Maryjane, Tang, W.H. Wilson, Bhimaraj, Arvind, Czer, Lawrence, Hall, Shelley, Haririan, Abdolreza, Formica, Richard N., Patel, Jignesh, Skorka, Rafael, Fedson, Savitri, Srinivas, Titte, Testani, Jeffrey, Yabu, Julie M., and Cheng, Xingxing S.

Published
2021
Full Text
View/download PDF

26. Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF.

Author

Martens, Pieter, Greene, Stephen J., Mentz, Robert J., Li, Shuang, Wojdyla, Daniel, Kapelios, Chris J., Mullens, Wilfried, Hall, Michael E., Ketema, Fassil, Kim, Dong‐Yun, Eisenstein, Eric L., Anstrom, Kevin, Fang, James C., Pitt, Bertram, Velazquez, Eric J., and Tang, W.H. Wilson

Subjects
HEART failure, GLOMERULAR filtration rate, HOSPITAL care, DIURETICS, KIDNEY physiology
Abstract

Aim: Among patients discharged after hospitalization for heart failure (HF), a strategy of torsemide versus furosemide showed no difference in all‐cause mortality or hospitalization. Clinicians have traditionally favoured torsemide in the setting of kidney dysfunction due to better oral bioavailability and longer half‐life, but direct supportive evidence is lacking. Methods and results: The TRANSFORM‐HF trial randomized patients hospitalized for HF to a long‐term strategy of torsemide versus furosemide, and enrolled patients across the spectrum of renal function (without dialysis). In this post‐hoc analysis, baseline renal function during the index hospitalization was assessed as categories of estimated glomerular filtration rate (eGFR; <30, 30–<60, ≥60 ml/min/1.73 m2). The interaction between baseline renal function and treatment effect of torsemide versus furosemide was assessed with respect to mortality and hospitalization outcomes, and the change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ‐CSS). Of 2859 patients randomized, 336 (11.8%) had eGFR <30 ml/min/1.73 m2, 1138 (39.8%) had eGFR 30–<60 ml/min/1.73 m2, and 1385 (48.4%) had eGFR ≥60 ml/min/1.73 m2. Baseline eGFR did not modify treatment effects of torsemide versus furosemide on all adverse clinical outcomes including individual components or composites of all‐cause mortality and all‐cause (re)‐hospitalizations, both when assessing eGFR categorically or continuously (p‐value for interaction all >0.108). Similarly, no treatment effect modification by eGFR was found for the change in KCCQ‐CSS (p‐value for interaction all >0.052) when assessing eGFR categorically or continuously. Conclusion: Among patients discharged after hospitalization for HF, there was no significant difference in clinical and patient‐reported outcomes between torsemide and furosemide, irrespective of renal function. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: Mechanistic insights into sodium handling

Author

Dauw, Jeroen, primary, Meekers, Evelyne, additional, Martens, Pieter, additional, Deferm, Sébastien, additional, Dhont, Sebastiaan, additional, Marchal, Wouter, additional, Mesotten, Liesbeth, additional, Dupont, Matthias, additional, Nijst, Petra, additional, Tang, W.H. Wilson, additional, Janssens, Stefan P., additional, and Mullens, Wilfried, additional

Published
2024
Full Text
View/download PDF

29. Effects of Pirfenidone on Echocardiographic Parameters of Left Ventricular Structure and Function in Patients with Idiopathic Pulmonary Fibrosis

Author

Al-Ansari Shehab, Borowski Allen, Fuad Ali, Alawadhi Omar, Riaz Haris, Sharma Vikram, Khan Nauman, Southern Brian D., and Tang W.H. Wilson

Subjects
pirfenidone, idiopathic pulmonary fibrosis, heart failure, myocardial dysfunction, Medicine
Abstract

Aim: Pirfenidone is a novel anti-fibrotic agent utilized in the treatment of idiopathic pulmonary fibrosis (IPF). It has been implicated in mitigating myocardial fibrosis and left ventricular (LV) systolic and diastolic dysfunction in animal models. However, its impact on LV mechanics in humans remains unknown. The aim of this study was to retrospectively evaluate the effects of pirfenidone on echocardiographic parameters of LV function and structure in patients with IPF.

Published
2020
Full Text
View/download PDF

34. Prognostic value of gut microbe‐generated metabolite phenylacetylglutamine in patients with heart failure.

Author

Tang, W.H. Wilson, Nemet, Ina, Li, Xinmin S., Wu, Yuping, Haghikia, Arash, Witkowski, Marco, Koeth, Robert A., Demuth, Ilja, König, Maximilian, Steinhagen‐Thiessen, Elisabeth, Bäckhed, Fredrik, Fischbach, Michael A., Deb, Arjun, Landmesser, Ulf, and Hazen, Stanley L.

Subjects
*PROGNOSIS, *HEART failure patients, *LIQUID chromatography-mass spectrometry, *VENTRICULAR ejection fraction, *GLOMERULAR filtration rate
Abstract

Aim: Phenylacetylglutamine (PAGln) is a phenylalanine‐derived metabolite produced by gut microbiota with mechanistic links to heart failure (HF)‐relevant phenotypes. We sought to investigate the prognostic value of PAGln in patients with stable HF. Methods and results: Fasting plasma PAGln levels were measured by stable‐isotope‐dilution liquid chromatography–tandem mass spectrometry (LC‐MS/MS) in patients with stable HF from two large cohorts. All‐cause mortality was assessed at 5‐year follow‐up in the Cleveland cohort, and HF, hospitalization, or mortality were assessed at 3‐year follow‐up in the Berlin cohort. Within the Cleveland cohort, median PAGln levels were 4.2 (interquartile range [IQR] 2.4–6.9) μM. Highest quartile of PAGln was associated with 3.09‐fold increased mortality risk compared to lowest quartile. Following adjustments for traditional risk factors, as well as race, estimated glomerular filtration rate, amino‐terminal pro‐B‐type natriuretic peptide, high‐sensitivity C‐reactive protein, left ventricular ejection fraction, ischaemic aetiology, and HF drug treatment, elevated PAGln levels remained predictive of 5‐year mortality in quartile comparisons (adjusted hazard ratio [HR] [95% confidence interval, CI] for Q4 vs Q1: 1.64 [1.07–2.53]). In the Berlin cohort, a similar distribution of PAGln levels was observed (median 3.2 [IQR 2.0–4.8] μM), and PAGln levels were associated with a 1.92‐fold increase in 3‐year HF hospitalization or all‐cause mortality risk (adjusted HR [95% CI] for Q4 vs Q1: 1.92 [1.02‐3.61]). Prognostic value of PAGln appears to be independent of trimethylamine N‐oxide levels. Conclusion: High levels of PAGln are associated with adverse outcomes independent of traditional cardiac risk factors and cardio‐renal risk markers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. The Utilization and Impact of Cardiovascular Specialists on Guideline‐Directed Medical Scores: An Analysis of a Diverse, Multi‐state, Electronic Health Record‐Based Registry

Author

Martyn, Trejeeve, primary, Saef, Joshua, additional, Khot, Umesh N., additional, Martinez, Kathryn A., additional, Brophy, Todd J., additional, West, Lucianne, additional, Cristiani, Cari, additional, Block‐Beach, Hunter, additional, Hohman, Jessica A., additional, Sobol, Tim, additional, Brooksbank, Jeremy A., additional, Surratt, Michael B., additional, Babiuch, Christopher, additional, Kapadia, Samir R., additional, Tang, W.H. Wilson, additional, Estep, Jerry D., additional, and Starling, Randall C., additional

Published
2023
Full Text
View/download PDF

38. L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans

Author

Koeth, Robert A., Lam-Galvez, Betzabe Rachel, Kirsop, Jennifer, Wang, Zeneng, Levison, Bruce S., Gu, Xiaodong, Copeland, Matthew F., Bartlett, David, Cody, David B., Dai, Hong J., Culley, Miranda K., Li, Xinmin S., Fu, Xiaoming, Wu, Yuping, Li, Lin, DiDonato, Joseph A., Tang, W.H. Wilson, Garcia-Garcia, Jose Carlos, and Hazen, Stanley L.

Subjects
Carnitine -- Research, Omnivores -- Research, Microbiota (Symbiotic organisms) -- Research, Health care industry
Abstract

BACKGROUND. L-Carnitine, an abundant nutrient in red meat, accelerates atherosclerosis in mice via gut microbiota- dependent formation of trimethylamine (TMA) and trimethylamine N-oxide (TMAO) via a multistep pathway involving an atherogenic intermediate, [gamma]-butyrobetaine ([gamma]BB). The contribution of [gamma]BB in gut microbiota- dependent L-carnitine metabolism in humans is unknown.METHODS. Omnivores and vegans/vegetarians ingested deuterium-labeled L-carnitine ([d.sub.3]-L-carnitine) or [gamma]BB ([d.sub.9]-[gamma]BB), and both plasma metabolites and fecal polymicrobial transformations were examined at baseline, following oral antibiotics, or following chronic ([greater than or equal to] 2 months) L-carnitine supplementation. Human fecal commensals capable of performing each step of the L-carnitine [right arrow] [gamma]BB [right arrow] TMA transformation were identified.RESULTS. Studies with oral [d.sub.3]-L-carnitine or [d.sub.9]-[gamma]BB before versus after antibiotic exposure revealed gut microbiota contribution to the initial 2 steps in a metaorganismal L-carnitine [right arrow] [gamma]BB [right arrow] TMA [right arrow] TMAO pathway in subjects. Moreover, a striking increase in [d.sub.3]-TMAO generation was observed in omnivores over vegans/vegetarians (>20-fold; P = 0.001) following oral [d.sub.3]-L-carnitine ingestion, whereas fasting endogenous plasma L-carnitine and [gamma]BB levels were similar in vegans/ vegetarians (n = 32) versus omnivores (n = 40). Fecal metabolic transformation studies, and oral isotope tracer studies before versus after chronic L-carnitine supplementation, revealed that omnivores and vegans/vegetarians alike rapidly converted carnitine to [gamma]BB, whereas the second gut microbial transformation, [gamma]BB [right arrow] TMA, was diet inducible (L-carnitine, omnivorous). Extensive anaerobic subculturing of human feces identified no single commensal capable of L-carnitine [right arrow] TMA transformation, multiple community members that converted L-carnitine to [gamma]BB, and only 1 Clostridiales bacterium, Emergencia timonensis, that converted [gamma]BB to TMA. In coculture, E. timonensis promoted the complete L-carnitine [right arrow] TMA transformation.CONCLUSION. In humans, dietary L-carnitine is converted into the atherosclerosis- and thrombosis-promoting metabolite TMAO via 2 sequential gut microbiota-dependent transformations: (a) initial rapid generation of the atherogenic intermediate [gamma]BB, followed by (b) transformation into TMA via low-abundance microbiota in omnivores, and to a markedly lower extent, in vegans/vegetarians. Gut microbiota [gamma]BB [right arrow] TMA/TMAO transformation is induced by omnivorous dietary patterns and chronic L-carnitine exposure.TRIAL REGISTRATION. ClinicalTrials.gov NCT01731236.FUNDING. NIH and Office of Dietary Supplements grants HL103866, HL126827, and DK106000, and the Leducq Foundation., IntroductionRecent studies identify a mechanistic link between a Western diet, gut microbiota-dependent metabolism, and development of both cardiovascular disease (CVD) and metabolic diseases (1-3). For example, the ingestion of trimethylamine-containing [...]

Published
2019
Full Text
View/download PDF

40. Sodium and potassium changes during decongestion with acetazolamide – a pre‐specified analysis from the ADVOR trial

Author

Dhont, Sebastiaan, primary, Martens, Pieter, additional, Meekers, Evelyne, additional, Dauw, Jeroen, additional, Verbrugge, Frederik H., additional, Nijst, Petra, additional, ter Maaten, Jozine M., additional, Damman, Kevin, additional, Mebazaa, Alexandre, additional, Filippatos, Gerasimos, additional, Ruschitzka, Frank, additional, Tang, W.H. Wilson, additional, Dupont, Matthias, additional, and Mullens, Wilfried, additional

Published
2023
Full Text
View/download PDF

42. Screening for Dilated Cardiomyopathy in At-Risk First-Degree Relatives

Author

Ni, Hanyu, primary, Jordan, Elizabeth, additional, Kinnamon, Daniel D., additional, Cao, Jinwen, additional, Haas, Garrie J., additional, Hofmeyer, Mark, additional, Kransdorf, Evan, additional, Ewald, Gregory A., additional, Morris, Alanna A., additional, Owens, Anjali, additional, Lowes, Brian, additional, Stoller, Douglas, additional, Tang, W.H. Wilson, additional, Garg, Sonia, additional, Trachtenberg, Barry H., additional, Shah, Palak, additional, Pamboukian, Salpy V., additional, Sweitzer, Nancy K., additional, Wheeler, Matthew T., additional, Wilcox, Jane E., additional, Katz, Stuart, additional, Pan, Stephen, additional, Jimenez, Javier, additional, Fishbein, Daniel P., additional, Smart, Frank, additional, Wang, Jessica, additional, Gottlieb, Stephen S., additional, Judge, Daniel P., additional, Moore, Charles K., additional, Huggins, Gordon S., additional, and Hershberger, Ray E., additional

Published
2023
Full Text
View/download PDF

46. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure

Author

Aimo, Alberto, Vergaro, Giuseppe, Ripoli, Andrea, Bayes-Genis, Antoni, Pascual Figal, Domingo A., de Boer, Rudolf A., Lassus, Johan, Mebazaa, Alexandre, Gayat, Etienne, Breidthardt, Tobias, Sabti, Zaid, Mueller, Christian, Brunner-La Rocca, Hans-Peter, Tang, W.H. Wilson, Grodin, Justin L., Zhang, Yuhui, Bettencourt, Paulo, Maisel, Alan S., Passino, Claudio, Januzzi, James L., and Emdin, Michele

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results